

Index

- abciximab, 344
 ABO blood group system, 350–1
 acetazolamide, 325, 433
 acetylcholine (ACh), 231–2, 235–6, 268–70
 acetylcholine receptors (AChRs), 235–8, 270
 acetylcholinesterase (AChE), 20, 235–6
 acid-base balance
 albumin, 372
 anion gap, 331–2
 base excess, 331
 Brønsted-Lowry acids and bases, 329
 complex disturbances in critical care patients, 337
 definition of acid, 329
 disorders of, 330–1
 Haldane and Bohr effects, 38
 $\text{HCO}_3^-/\text{H}_2\text{CO}_3$ buffer system, 330, 332
 hypothermic cardiopulmonary bypass, 336
 K_a , 329
 pH (See pH)
 pK_a , 329–30
 Stewart approach, 336–7
 systemic consequences of disturbances, 334–5
 acidosis, 330–5, 354, 375, 382
 actin, 241–4
 action potential, 4, 225, 244. *See also*
 cardiac action potential; nerve action potential
 active immunisation, 365–6
 active transport, 15–16, 200, 413–17
 acute coronary syndrome (ACS), 141
 acute high-altitude illness, 433
 acute kidney injury (AKI), 311
 acute mountain sickness (AMS), 433
 acute pancreatitis, 292
 adaptive immune system, 2, 360
 adenosine, 256
 adenosine diphosphate (ADP) receptor antagonists, 344
 adenosine triphosphate (ATP), 179, 242–4, 373, 377–8
 adrenal glands, 310, 401–4
 adrenaline, 122, 151, 153, 261, 270–1, 382, 402–4
 adrenergic receptors, 270–1
 adrenocorticotrophic hormone (ACTH), 393, 402
 aerobic metabolism, 74, 374, 377–8
 afferent neurons. *See* sensory neurons
 afterload, 121–3, 137–8, 180
 ageing, 119–20, 422–6
 airway
 changes of pregnancy, 406–7
 closure of small, 51
 lower (See lower airways)
 obesity effects, 427
 paediatric, 418–19
 spinal cord injury patients, 219–20
 thyroid surgery complications, 398–9
 upper, 21–3, 60, 62, 89
 airway devices, 91, 108
 airway obstruction, 60–2
 airway resistance, 88–92
 albumin, 304, 332, 371–2
 alcohol, 303, 332
 aldosterone, 310, 401–2
 alkalosis, 330–1, 333–5
 allele, 11
 allergen, 360, 369
 allergic reactions, 260, 353, 368–9
 allodynia, 275
 allogenic blood transfusion, 351
 allopurinol, 311
 alteplase, 348
 altitude physiology, 42–3, 77–9, 100, 431–3
 aluminium hydroxide, 285
 alveolar dead space, 45–6
 alveolar diffusion, 40–3, 63–4
 alveolar gas equation (AGE), 77–9, 431
 alveolar partial pressure of oxygen ($P_A\text{O}_2$), 77–80, 431
 alveolar ventilation (\dot{V}_A), 46–7, 68–9, 77, 86–7, 104, 419. *See also*
 ventilation-perfusion mismatch;
 ventilation-perfusion ratio
 alveolar volume (V_A), 45
 alveolar-arterial (A-a) gradient, 78
 alveolar-capillary barrier, 27, 40, 42–3, 81
 alveoli, 26–7, 77, 80, 83–4
 amiloride, 325
 amino acids, 201, 300, 332, 378–80, 391
 aminoglycosides, 237, 311
 amiodarone, 255–6
 ammonia, 201, 305
 ammoniogenesis, 334
 amylase, 279, 292
 anaemia, 75, 356–8
 anaemic hypoxia, 63
 anaerobic metabolism, 32–3, 74, 81, 374–5, 377–8
 anaesthetic agents
 effects on CBF, 204
 effects on thermoregulatory mechanisms, 436–7
 hepatic blood flow effects, 296
 immune system depression, 370
 inotropic effects, 122
 intravenous, 107, 204, 413, 426
 mechanism of action, 229, 233–4
 obesity effects, 428–9
 pharmacokinetic differences between children and adults, 421
 physiological changes with ageing, 426
 reduced stress response, 389
 respiratory system effects, 107–8
 spinal cord injury patients, 220
 TCI programs, 429
 transport across placenta, 413
 ventilation control effects, 96
 volatile (See volatile anaesthetic agents)
 anaphylaxis, 368–9
 anatomical dead space, 25, 45, 47–8
 angina, 162
 angiotensin II, 151, 310, 401–2
 angiotensin-converting enzyme (ACE) inhibitors, 29
 anion gap, 331–2
 anorexia nervosa, 385–6
 Anrep effect, 123
 antacids, 285, 409
 anterior spinal artery syndrome, 212–13, 218
 anti-anginal drugs, 162
 antiarrhythmic drugs, 255–6
 antibiotics, 369
 antibodies, 350–1, 363–9, 412
 anticholinesterases, 236, 281

Index

- anticoagulant therapy, 347–8
 anti-diuretic hormone (ADH), 151,
 173, 310, 320–1, 323, 325, 394–5
 antiemetic drugs, 288
 antifibrinolytic drugs, 348–9
 antigens, 350–1, 360
 antioxidants, 102
 antiplatelet drugs, 115, 143, 343–4
 anti-RhD immunoglobulin, 351
 antiseptics, 369
 anti-thyroid drugs, 398
 aorta, 155
 aortic stenosis, 120, 123–4
 aortocaval compression, 408–9
 apixaban, 347–8
 apneustic centre, 93
 apnoea, 30, 39, 51, 434
 appetite, 428
 aqueous humour, 276–8
 arginine vasopressin. *See* anti-diuretic
 hormone
 arrhythmia, 144, 166, 171, 255–6, 419
 arterial baroreceptor reflex, 170–1
 arterial pressure waveform, 152–3,
 155–7
 arterial system, 146–53, 194–6, 424
 arterial tension of carbon dioxide
 ($P_a\text{CO}_2$), 46–7, 65, 104, 203–4, 407
 arterial tension of oxygen ($P_a\text{O}_2$), 63,
 67, 81, 182, 203–4
 arteries, 148, 163–4, 249
 arterioles, 150–2, 172
 arteriovenous malformation (AVM),
 64
 aspiration pneumonia, 280–1
 aspirin, 314, 343–4
 asthma, 43, 56–8, 72, 368–9, 427
 asthma-COPD overlap syndrome
 (ACOS), 56–8
 astrocytes, 194
 atelectasis, 108–9
 atheroma, 115
 athletes, exercise physiology, 183–4
 ATPases, 14, 16, 223
 atracurium, 107, 426
 atrium, 111
 atrophy, muscle, 245
 atropine, 261, 281, 413, 420
 autologous blood transfusion, 351
 autonomic nervous system (ANS), 1,
 115, 176–7, 191, 204, 250, 258–60,
 267–71, 294, 420
 autosomal dominant inheritance,
 11–12
 autosomal recessive inheritance, 11–12
 axons, 189, 226–7
- Bain circuit (Mapleson D), 47
 Bainbridge reflex, 170–1
- balloon-tipped flow-directed PAC, 101,
 125–7
 Bamford classification, 195–6
 barbiturates, 421
 barometric pressure, 77–9, 431
 baroreceptors, arterial, 170–1
 barotrauma, 51
 basal ganglia, 192
 basal metabolic rate (BMR), 383, 420–1
 base, 329. *See also* acid-base balance
 base excess (BE), 331
 basophils, 361
 Bazett's formula, 262–3
 Becker's muscular dystrophy (BMD),
 244–5
 bendroflumethiazide, 325
 benzodiazepines, 107, 201, 234, 426
 β -blockers, 115, 122, 255–6
 β -human chorionic gonadotropin
 (β -hCG), 405
 β -oxidation, 378–9, 384
 bicarbonate (HCO_3^-)
 CO_2 transport as, 37–9
 controlled reabsorption, 333–4
 $\text{HCO}_3^-/\text{H}_2\text{CO}_3$ buffer system, 330,
 332
 hyperkalaemia management, 327
 pancreatic synthesis of, 292–3
 bile, 297, 300–1
 bilirubin, 300–2, 305
 birth, 416–17
 bisoprolol, 256, 270–1
 bladder, 338–9
 bleeding. *See* haemorrhage
 bleomycin, 103
 blood. *See also* haemostasis
 changes of pregnancy, 408
 CO_2 transport in, 37–9
 components, 371
 foetal and maternal, 411
 management, 357
 O_2 transport in, 30
 reducing volume to manage
 increased ICP, 208
 blood pressure. *See also* mean arterial
 pressure
 changes with ageing, 424
 exercise effects, 180
 factors determining, 153
 importance of minimising
 fluctuations, 170
 manipulation, 153
 measurements, 152–3
 blood products, 352–3
 blood substitutes, 355
 blood transfusion, 33
 ABO blood group system, 350–1
 allogenic and autologous, 351
 antibodies to RBC antigens, 350–1
- cell salvage, 353–4
 complications, 353
 cross-match, 352
 haemolytic transfusion reaction,
 351–2
 massive, 354
 O_2 -carrying solutions, 355
 RBC antigens, 350–1
 Rhesus blood group system, 350–1,
 412
 Rhesus disease, 351
 storage of blood products, 352–3
 universal donors and recipients,
 352
 blood velocity, 145–7
 blood–brain barrier (BBB), 158, 200–1,
 420
 body
 control mechanisms, 3–5
 general organisation, 1–5
 homeostasis, 2–3
 organs, 1–2
 systems, 1–2
 body fluid compartments, 318, 421
 body plethysmography, 53–4
 Bohr effect, 32, 38, 414
 Bohr equation, 48–9
 bone mineral density, 184
 botulinum toxin, 237
 Bowditch effect, 123
 Boyle's law, 53–4
 brain, 191
 angiotensin II effects, 310
 blood flow (*See* cerebral blood flow)
 cerebral arterial blood supply,
 194–6
 changes with ageing, 424
 EEG, 196–7
 glucose requirement, 384
 gross anatomy, 192–3
 meninges, 193–4
 metabolism, 203, 208
 neuroglia, 194
 pain signal pathways to, 273
 proportion of cardiac output
 directed to, 202
 reducing volume to manage
 increased ICP, 208–9
 stroke, 195–6
 venous drainage, 195
 brain injury, 209–10
 breath-hold diving, 434–5
 bronchi, 26, 249
 bronchial circulation, 97
 bronchioles, 26
 Brown-Séquard syndrome, 214, 219
 buffering, 330, 332
 bumetanide, 325
 bupivacaine, 261, 421

- calcitonin, 400–1
 calcium (Ca^{2+})
 blood transfusion, 354
 cardiac action potential, 253
 cardiac muscle contraction, 258
 hyperkalaemia management, 327
 hyperparathyroidism effects, 401
 kidney and liver dysfunction effects, 401
 physiological functions, 399
 plasma proportion and regulation, 399–401
 in pregnancy, 406
 release of neurotransmitters, 232–3, 236
 resting membrane potential, 224
 skeletal muscle contraction, 241–4
 smooth muscle contraction, 250
 calcium carbonate, 285
 calcium channel blockers, 115, 122, 255–6
 calcium channels, 253–5
 calmodulin, 250
 capillaries, 146–7
 BBB, 158, 200
 control of blood flow through, 161
 haemorrhage and, 161
 pulmonary, 26–7
 roles, 158
 Starling filtration forces in
 transmembrane fluid flow, 159–61
 tissue exchange, 158–9
 types, 158
 carbimazole, 398
 carbohydrate, 290, 299, 373, 380–1, 385, 387
 carbon dioxide (CO_2)
 alveolar diffusion of, 40–1
 arterial tension (*See* arterial tension of carbon dioxide)
 binding, 37–8
 dissociation, 39
 effects on CBF, 203–4
 $\text{HCO}_3^-/\text{H}_2\text{CO}_3$ buffer system, 330, 332
 production and storage, 37
 regulation, 2
 transport, 37–9
 carbon monoxide (CO), 35–6, 41–3
 carbonic anhydrase (CA), 18–19, 37–8, 284–5, 292–3
 carbonic anhydrase (CA) inhibitors, 325
 carboxyhaemoglobin, 34–6
 cardiac action potential
 action of pacemaker currents, 256–7
 ANS influence on, 258–60
 antiarrhythmic drugs, 255–6
 conduction through heart, 257–8
 differences from nerve action potential, 252–3
 generation by pacemaker cells, 255–6
 in heart transplant patients, 261
 local anaesthetic toxicity, 259–61
 pacemaker potential, 256
 phases, 253–5
 refractory periods, 255
 cardiac arrhythmias, 144, 166, 171, 255–6, 419
 cardiac axis, 264–6
 cardiac cycle, 117–20
 cardiac failure, 132–5, 139–40, 160–1
 cardiac index (CI), 123, 419
 cardiac ischaemia, 122
 acute coronary syndrome, 141
 ECG changes, 142–3
 myocardial infarction, 141–3
 OER of heart compared with other organs, 141
 preconditioning, 144
 reperfusion injury, 143–4
 cardiac muscle
 ANS influence on, 258–60
 excitation-contraction coupling, 258
 Frank-Starling law, 131–2
 functional syncytium, 111–12
 heart transplants, 261
 local anaesthetic toxicity, 259–61
 mechanism of contraction, 258
 resting membrane potential, 252
 structural features, 252
 termination of contraction, 258
 cardiac output (CO)
 aortic stenosis and, 123–4
 blood pressure effects, 153
 Bowditch effect, 123
 cardiac index equation, 123
 changes of pregnancy, 408
 changes with ageing, 424
 elite athletes, 183
 equation, 121
 exercise effects, 180
 factors affecting, 121
 information from arterial pressure waveform, 156
 insufficient, 132
 invasive methods of measuring, 124–8
 MAP relationship, 121, 123
 minimally invasive methods of measuring, 124, 128–9
 non-invasive methods of measuring, 124
 proportion directed to brain, 202
 regulation, 121–3
 stroke volume index equation, 123
 tachycardia and, 119–20, 122–3
 Valsalva manoeuvre effects, 175–6
 cardiac pressure–volume loops
 left ventricular, 136–40
 right ventricular, 139–40
 cardiac resynchronisation therapy (CRT), 113–14
 cardiogenic pulmonary oedema, 100
 cardiogenic shock, 153
 cardiopulmonary bypass, 336
 cardiopulmonary exercise testing (CPET), 75–6, 185–6
 cardiotoxicity, local anaesthetic, 260–1
 cardiovascular reflexes
 arterial baroreceptor reflex, 170–1
 Bainbridge reflex, 170–1
 consequences of chemoreceptor activation, 170–1
 Cushing's reflex, 172
 foetal, 416
 in heart transplant patients, 261
 importance of minimising blood pressure fluctuations, 170
 physiological responses to haemorrhage, 172–3
 regulation of MAP, 170
 cardiovascular system, 1. *See also* pulmonary circulation; systemic circulation
 adrenaline effects, 403–4
 altitude adaptations, 432
 cardiac anatomy and function, 111–16
 changes at birth, 417
 changes of pregnancy, 407–9
 changes with ageing, 424
 coronary circulation, 112–13
 cortisol effects, 402
 effects of acid-base disturbances, 334–5
 elite athletes, 183
 exercise effects, 180–1
 hypothermia effects, 437
 obesity effects, 427–8
 paediatric, 419–20
 spinal cord injury effects, 217
 stress response effects, 388
 Valsalva manoeuvre effects, 175–6
 catabolism, protein, 373, 378–80, 388
 catalysts, 18
 catecholamines, 201, 314, 391, 402–4
 cauda equina syndrome, 219
 cell
 basic layout, 6–7
 nucleus, 6–7
 organelles, 7–8
 cell membrane, 6
 capacitance, 226–7
 depolarisation, 225–6
 phospholipid bilayer, 13
 resistance, 226

Index

- cell membrane (cont.)
 resting membrane potential, 221–3
 structures found within, 13–14
 transmembrane proteins, 14
 transport across, 14–17
- cell salvage, 353–4
- cell-mediated immunity, 366–7
- cellular respiration, 373
- central cord syndrome, 218–19
- central nervous system (CNS), 1, 191
 brain (*See* brain)
 changes of pregnancy, 410
 changes with ageing, 424
 effects of acid-base disturbances, 335
 hypothermia effects, 437
 ischaemic response, 170
 local anaesthetic toxicity, 260
 meninges, 193–4
 neuroglia, 194
 O₂ toxicity, 102
 paediatric, 420
 spinal cord (*See* spinal cord)
- central venous cannulation, 168
- central venous pressure (CVP), 121, 167
- central venous pressure (CVP)
 waveform, 166
- centrilobular necrosis, 297–8
- cerebellum, 193
- cerebral arterial blood supply, 194–6
- cerebral blood flow (CBF), 202–5, 207–8, 210
- cerebral cortex, 95, 192
- cerebral metabolic rate (CMR), 203, 208
- cerebral perfusion pressure (CPP), 202, 207–8, 210
- cerebrospinal fluid (CSF), 198–9, 208
- cerebrum, 192
- chemoreceptors, 93–4, 170–1
- chest wall movement, 104
- chloride (Cl⁻), 221–3
- chloride channels, 233
- cholecystokinin (CCK), 293
- choroid plexus, 198, 201
- chromosomes, 9
- chronic kidney disease (CKD), 401
- chronic obstructive pulmonary disease (COPD), 46, 56–8, 105
- chyle, 169
- chylomicrons, 291
- chylothorax, 168
- ciclosporin, 303
- Cinacalcet, 401
- circle of Willis, 194–6
- circle system, 47
- circumventricular organs, 201
- cirrhosis, 304, 401
- citric acid cycle, 373, 375–6
- clearance, renal, 314–16
- clonidine, 270, 274
- clopidogrel, 344
- closing capacity (CC), 47–8, 55, 419
- clotting, 341–7
- coagulation, 341, 345–6
- coagulation cascade, 342–5
- cocaine, 235
- codeine, 303
- codon, 10
- coeliac plexus blockade, 268
- coenzymes, 19
- cofactors, 19
- compensated heart failure, 133–4
- complement system, 362–3, 367
- complex regional pain syndrome (CRPS), 275
- conducting cells, 252, 256–7
- congestive cardiac failure, 132, 160–1
- contact dermatitis, 369
- cooperative binding, 31–2
- coronary blood flow, 114–16
- coronary circulation, 112–13
- coronospinal tract, 212, 215–16
- corticosteroids, 245
- corticotropin-releasing hormone (CRH), 402
- cortisol, 173, 387–8, 402
- creatinine, 314, 316
- cross-match, 352
- Cushing's reflex, 172
- Cushing's triad, 207–8
- cyanide poisoning, 36
- cyanohaemoglobin, 34
- cyclizine, 288
- cyclo-oxygenase (COX), 362
- cyclo-oxygenase (COX) inhibitors, 343–4
- cystatin C, 316
- cystic fibrosis, 11
- cytochrome P450 enzyme system, 20, 303, 347
- cytokines, 361–2, 387
- cytoplasm, 7
- cytotoxic hypoxia, 63
- cytotoxic T cells, 366–7
- dabigatran, 347–8
- dantrolene, 242
- Darcy's law, 97–8, 123, 151–2
- dead space, 25, 45–9, 108
- dead-space ventilation, 46
- death, starvation, 384–5
- decompensated heart failure, 134–5
- decompensated shock, 173
- decompression sickness, 435
- deflation, lung, 27–8
- demyelinating disease, 228–9
- dendrites, 189
- denervation hypersensitivity, 237–8
- deoxyribonucleic acid (DNA), 9–11
- depolarising muscle relaxants, 237–8
- desflurane, 107, 428–9
- desmopressin (DDAVP), 345
- dexamethasone, 209, 433
- dextrose infusion, 319–20, 327
- diabetes insipidus (DI), 323
- diabetic ketoacidosis, 382
- dialysis, 316–17
- diamorphine, 201
- diaphragm, 27, 419
- diastole, 117
- diastolic blood pressure (DBP), 152–3
- diazepam, 421
- diencephalon, 192–3
- dietary nutrients, 290
 carbohydrate digestion and absorption, 290
 lipid digestion and absorption, 291
 protein digestion and absorption, 290–1
 respiratory quotient for, 77–8
- diffusion capacity of the lung for carbon monoxide (DLCO), 42–3, 61
- diffusion limitation, 63–4
- digestion, 283, 289–93
 lymphatic system role, 169
 saliva role in, 279
- digoxin, 122–3, 256, 371–2
- dipyridamole, 344
- direct factor Xa inhibitors, 347–8
- direct oral anticoagulants (DOACs), 347–8
- direct thrombin inhibitors, 347–8
- dissociated sensory loss, 214–15
- diving, 89, 176, 434–5
- diving reflex, 434
- dobutamine, 122, 153
- domperidone, 288
- dopamine, 201, 235, 402–3
- Doppler equation, 128
- dorsal respiratory group (DRG), 93
- double Bohr effect, 414
- double Haldane effect, 414
- double-lumen ETTs (DLETTs), 26
- doxapram, 96
- doxazosin, 270
- drug excretion, 314
- drug metabolism, 303
- Duchenne's muscular dystrophy (DMD), 244
- duodenum, 285–6, 289
- dynamic compliance, 84–6
- dynamic exercise, 178
- edoxaban, 347–8
- eicosanoids, 310–11, 362, 391

- ejection fraction (EF), 119
 electrocardiogram (ECG), 142–3, 262–6
 electroencephalogram (EEG), 196–7
 electrolytes, 2. *See also specific electrolytes*
 disturbances, 223
 effects of acid-base disturbances, 335
 stress response effects, 388
 electron transport chain, 36, 373, 376–7
 Embden-Meyerhof pathway. *See glycolysis*
 empysemata, 51–2
 endocrine signalling, 189
 endocrine system, 2. *See also hormones; specific glands*
 changes with ageing, 425
 effects of pregnancy, 405–6
 intestinal motility, 294
 obesity effects, 428
 stress response, 387
 endoplasmic reticulum (ER), 8
 endoscopic third ventriculostomy, 199
 endothelin (ET), 162
 endothelium, 162, 341
 endotracheal tubes (ETTs), 26, 91, 108, 418–19
 enflurane, 107
 enhanced recovery, 385
 enoximone, 122
 enteric nervous system, 1, 294
 enzymes, 14, 18–20
 eosinophils, 361
 ependymal cells, 194
 ephedrine, 426
 epidural anaesthesia, 389, 408, 410
 erythromycin, 294, 303
 erythropoiesis, 356
 erythropoietin (EPO), 356, 358
 esmolol, 20, 153
 ether, 107
 ethylene glycol, 332
 etomidate, 204, 234, 389, 402
 excess post-exercise O₂ consumption (EPOC), 183–4
 excitation-contraction coupling, 4–5, 241–2, 250–1, 258, 399
 exercise physiology, 178
 alveolar diffusion effects, 42–3
 body system effects, 180–2
 changes in anticipation of exercise, 179–80
 changes in elite athletes, 183–4
 dynamic, 178
 heart rate, 122
 in heart transplant patients, 261
 lung perfusion, 68
 meaning of $\dot{V}O_{2\max}$, 182–3
 muscle fatigue, 179
 O₂ consumption after exercise, 183–4
 skeletal muscle energy sources, 179
 skeletal muscle fibre types, 178–9
 static, 178
 exercise testing, 185–6
 expiratory flow–volume curve, 58–60
 expiratory reserve volume (ERV), 50
 external ventricular drain (EVD), 199, 206, 208
 extracellular fluid (ECF), 2–3, 318–20
 extrapyramidal tracts, 212
 eye, 276–8
 facilitated diffusion, 15–16, 200
 factors, clotting, 341, 344–5. *See also thrombin*
 Fahraeus–Lindqvist effect, 149
 farmer’s lung, 369
 fasting, 286–7, 293
 fat, 179, 291, 299, 373, 378–81, 388
 fed state, 293
 fentanyl, 29, 389, 428–9
 foetal haemoglobin (HbF), 33–4, 420
 foetal physiology
 changes at birth, 416–17
 circulation, 99, 415–17
 crossing of substances through placenta, 412–13
 differences between foetal and adult circulation, 415–16
 double Haldane effect, 414
 drug transport across placenta, 413
 labour and foetal cardiovascular reflexes, 416
 O₂ delivery, 413–14
 oxygenation during labour, 414–15
 placenta anatomy and functions, 411–12
 transitional circulation, 417
 fibrinolysis, 348–9
 Fick principle, 124–7
 Fick’s law, 40
 filtration fraction, 317
 flecainide, 255–6
 flow-directed balloon-tipped PAC, 101, 125–7
 flow–metabolism coupling, 203
 flow–volume curve, 58–60
 flow–volume loop, 60–2
 fluid management, CVP guidance, 167
 follicle-stimulating hormone (FSH), 393
 forced expiratory volume in 1 second (FEV₁), 56–8, 61
 forced vital capacity (FVC), 56–8
 Fowler’s method, 47–8
 fraction of inspired oxygen (F_iO₂), 43, 67, 77
 Frank–Starling law, 131–2, 134
 fresh frozen plasma (FFP), 352
 frontal lobe, 192
 functional residual capacity (FRC), 27, 50–5, 82, 108, 419
 functional syncytium, 111–12
 furosemide, 325
 ganglia, 267–70
 gas dilution technique, 52–3
 gastric acid, 283–5
 gastric acid inhibitors, 285
 gastric dumping syndrome, 285–6
 gastric emptying, 285–7
 gastrin, 283, 293
 gastrointestinal (GI) system, 2
 changes of pregnancy, 409
 liver (*See liver*)
 obesity effects, 428
 oesophagus, 280–1
 organs involved in digestion, 289
 pacemaker cells, 250
 pancreas, 291–3
 saliva, 279–80
 small intestine, 289–90, 293–4
 smooth muscle, 249
 spinal cord injury effects, 217
 stomach, 283–7
 swallowing, 280–1
 gastro-oesophageal reflux, 281, 409, 428
 gene mutations, 11
 general anaesthesia
 aortocaval compression response, 408–9
 aspiration of gastric contents, 281
 EEG monitoring, 196–7
 effects on thermoregulatory mechanisms, 436–7
 at high altitude, 433
 mechanism of action, 233–4
 post-operative visual loss, 278
 pregnancy and, 407
 pre-oxygenation for, 52
 reduced stress response, 389
 respiratory system effects, 108–10
 genetics, 9–12
 global O₂ consumption ($\dot{V}O_2$), 74–6, 181–6
 global O₂ delivery ($\dot{D}O_2$), 74–6
 glomerular filtration rate (GFR), 309–10, 314–16, 409
 glomerulus, 307, 313
 glucagon, 122, 381–4
 gluconeogenesis, 299, 380–1, 384
 glucose
 amount of ATP generated from, 377–8

Index

- glucose (cont.)
 insulin and glucagon regulation, 381–3
 maintenance during starvation, 384
 physiological response to haemorrhage, 172
 preoperative loading, 385
 reabsorption in PCT, 314
 stress response effects, 387–8
 uptake, 382
- glyceryl trinitrate, 153, 162
 glycine, 231
 glycogen, 179, 239, 380
 glycogenesis, 299, 380–1
 glycogenolysis, 299, 380–1, 384
 glycolysis, 179, 299, 373–5
 glycoprotein IIb/IIIa inhibitors, 344
 glycopyrrolate, 261, 281, 413
 glycosuria, 314, 409
 lymphatic system, 198
 Goldman–Hodgkin–Katz equation, 222–3
 Golgi apparatus, 8
 Golgi tendon organs, 246–7
 graft-versus-host disease, 353
 Graham's law, 40
 Graves' disease, 398
 growth hormone (GH), 393–4
 Guillain–Barré syndrome, 57–8, 228–9
- haemochromatosis, 358
 haemoglobin (Hb), 30
 causes of anaemia, 356–7
 CO binding, 35–6
 CO₂ binding, 37–8
 cyanide binding to, 36
 foetal, 33–4, 420
 O₂ binding, 31–2
 O₂ dissociation, 32–3
 physiological and pathological forms, 34
 regulation of pH, 332
 in sickle cell disease, 34
 structure, 31
- haemolytic disease of the newborn, 412
 haemolytic transfusion reaction, 351–2
 haemophilia, 345
 haemorrhage, 5, 161, 172–3, 357
 haemorrhagic shock, 173
 haemostasis, 4, 341
 altitude adaptations, 432
 antiplatelet drugs, 343–4
 cell-based model of coagulation, 345–6
 changes of pregnancy, 409
 clotting initiation, 342
 coagulation cascade, 342–5
 endothelium role in, 162, 341
 fibrinolysis pathway, 348–9
- haemophilia and von Willebrand disease, 345
 hypothermia effects, 438
 laboratory tests of clotting, 346–7
 oral anticoagulants, 347–8
 platelet activation and aggregation, 342–3
 steps in clot formation, 341–2
 thromboelastography, 348
- Hagen–Poiseuille equation, 89, 148–50
 Haldane effect, 38, 414
 halothane, 107
 halothane hepatitis, 298
 hapten, 360
 haptocorrin, 279
 head injury, 209–10
- heart
 adrenergic effects, 403–4
 ANS influence on, 258–60
 cardiac action potential conduction through, 257–8
 cardiac action potential generation in, 255–6
 changes of pregnancy, 407–9
 changes with ageing, 424
 coronary blood flow, 114–16
 coronary circulation, 112–13
 CRT, 113–14
 electrophysiological activity, 263–4
 (See also electrocardiogram)
 excitation-contraction coupling, 4–5
 foetal, 416
 functional syncytium defined, 111–12
 functions, 111
 local anaesthetic toxicity, 260–1
 OER of, 141
 Starling's law of, 131–2, 134
 structure, 111
 venous drainage, 112–13
 venous return to, 163–5
- heart failure, 132–5, 139–40, 160–1
 heart rate (HR)
 altitude adaptations, 432
 blood pressure effects, 153
 cardiac action potential changes with, 254–6
 cardiac output regulation, 122
 changes with ageing, 424
 coronary blood flow regulation, 115
 elite athletes, 183
 exercise effects, 180
 Valsalva manoeuvre effects, 175–6
- heart transplantation, 261
 Heliox, 435
 hemicholinium, 236
 Henderson–Hasselbalch equation, 330
 heparan sulphate, 162, 341
 heparin therapy, 143, 347
- hepatitis, 298
 hepcidin, 358
 Hering–Breuer reflex, 94–5
 hexose monophosphate shunt. See pentose phosphate pathway
 high flow nasal oxygen (HFNO) therapy, 23
 high-altitude cerebral oedema (HACE), 433
 high-altitude pulmonary oedema (HAPE), 433
 histamine, 150, 284–5
 histamine H₂ receptor antagonists, 285
 histidine, 37
 homeostasis, 2–5
 hormones, 391
 anterior pituitary, 393–4
 appetite control, 428
 effects of pregnancy, 405–6
 hypothalamus secretion of, 393
 intestinal motility, 294
 liver functions influencing, 302
 pituitary adenoma effects, 395
 placental, 411
 posterior pituitary, 394–5
 smooth muscle input from, 250
 stress response, 387
 thyroid, 396–8, 406
 types, 391
- Horner's syndrome, 277
 human placental lactogen (hPL), 405
 humidification, artificial, 24, 108
 Huntington's disease, 11
 hydrocephalus, 199
 hydrochloric acid, 283
 hydroxocobalamin, 36
 hyoscine, 288
 hyperalgesia, 275
 hypercapnoea, 95–6, 104–5, 208, 210
 hyperglycaemia, 210, 314, 387–8
 hyperkalaemia, 223–4, 237–8, 326–7, 354
 hyperparathyroidism, 401
 hypersensitivity, 368–9
 hyperthyroidism, 396–8
 hyperventilation, 47, 77–9, 431
 hypocalcaemia, 224, 354, 398, 401
 hypocapnoea, 210
 hypoglycaemia, 210, 286, 421
 hypokalaemia, 223, 327–8
 hyponatraemia, 224, 320
 hypotension, 153
 hypotensive anaesthesia, 153
 hypothalamic-pituitary axis, 393–4
 hypothalamus, 193, 201, 310, 320, 323, 387, 391–3, 436
 hypothermia, 354, 370, 436–8
 hypothermic cardiopulmonary bypass, 336

- hypothyroidism, 396–7
 hypotonicity, 319–20
 hypoventilation, 63, 77–8
 hypovolaemia, 156–7
 hypoxaemia, 43, 63–5, 69–70, 95, 104, 208, 210
 hypoxia, 30, 63
 hypoxic pulmonary vasoconstriction (HPV), 70, 99–100, 432
 hysteresis, 85–6
- idarucizumab, 347–8
- immune system, 2
 adaptive, 2, 360
 allergens, 360, 369
 antibody functions and production, 363–5
 cell-mediated immunity, 366–7
 complement, 362–3, 367
 consequences of anaesthesia and surgery, 369–70
 definition of antigens, 360
 definition of inflammation, 361–2
 development of antibodies to RBC antigens, 350–1
 difference between active and passive immunisation, 365–6
 difference between primary and secondary response, 365
 eicosanoids and kinins involved in inflammation, 362
 haptens, 360
 hypersensitivity, 368–9
 immunodeficiency, 367
 immunoglobulin structure and types, 367–8
 innate, 2, 360–1
 lymphocyte maturation, 363
 lymphoid tissue, 363
 SIRS, 362
 stress response effects, 388
- immunisation, 365–6
 immunodeficiency, 367
 immunoglobulin (Ig), 363, 365–8, 412
 incomplete spinal cord injury, 218–19
 infant respiratory distress syndrome (IRDS), 84, 99–100
 inferior vena cava (IVC), 164–5
 inflammation, 162, 302, 361–2
 inflation, lung, 27–8
 inhalational anaesthetic agents. *See* volatile anaesthetic agents
 innate immune system, 2, 360–1
 inotropic drugs, 122, 153
 inspiratory capacity (IC), 50
 inspiratory flow–volume curve, 60–2
 inspiratory reserve volume (IRV), 50
 insulin, 381–5
 insulin therapy, 210, 327, 388
- integumentary system, 2
 intensive care, 103
 intensive care unit-acquired weakness (ICUAW), 245
 internal carotid arteries (ICAs), 194–5
 international normalised ratio (INR), 346–7, 371–2
 intestinal motility, 293–4
 intracellular fluid (ICF), 318
 intracranial pressure (ICP)
 CPP relationship to, 202, 207–8
 CSF and, 198
 Cushing's triad, 207–8
 extrinsic PEEP and, 24
 measurement, 206
 Monro-Kellie hypothesis, 206–7
 normal, 206
 paediatric, 420
 symptoms and signs of increased, 207
 ways to reduce, 208–9
- Intralipid[®], 261
 intramuscular drug administration, 169
 intraocular pressure (IOP), 277–8
 intraoperative hypothermia, 436–8
 intrapleural pressure (P_{p1}), 27–9
 intravenous anaesthetic agents, 107, 204, 413, 426
 intrinsic factor (IF), 283–4
 iodide, 396–7
 ion channels, 14–15
 ionotropic receptors, 233–4
 iron, 357–8
 iron overload, 353
 ischaemia preconditioning, 144
 ischaemic reperfusion injury (IRI), 143–4
 ischaemic stroke, 195–6
 isoflurane, 107, 428–9
 isoprenaline, 122
- jaundice, 301–2
 Jehovah's Witnesses, 355
 Jendrassik manoeuvre, 248
 jugular bulb catheterisation, 204
 juxtacapillary receptors (J-receptors), 95
 juxtaglomerular apparatus, 308–10
- K_a , 329
 ketamine, 107, 204, 220, 234, 413
 ketone bodies, 378, 384
 Kety-Schmidt technique, 205
- kidney
 ADH actions at, 320–1
 AKI pathophysiology, 311
 anatomy, 307
 autoregulation, 309–10
 changes of pregnancy, 409–10
 changes with ageing, 424–5
 clearance, 314–16
 disorders of osmolarity, 323
 effects of diuretics, 324–5
 eicosanoid regulation, 310–11
 excretion, 314
 filtration, 313
 filtration fraction, 317
 functions, 307
 GFR, 309–10, 314–16
 hypocalcaemia, 401
 hypothermia effects, 438
 juxtaglomerular apparatus, 308–10
 measurement of renal blood flow, 311
 nephron structure, 307–8
 osmolarity of renal medulla, 320–3
 paediatric, 420
 physiological response to haemorrhage, 172–3
 reabsorption, 313–14, 333–4
 regulation of K^+ , 326–8
 regulation of Na^+ , 318–19, 323–4
 regulation of pH, 333–4
 regulation of plasma osmolarity, 319–20, 325
 regulation of plasma volume, 318–19, 324–6
 regulation of renal blood flow, 309–11
 regulation of water (*See* water balance)
 renal replacement therapy, 316–17
 renin-angiotensin-aldosterone axis, 310
 Starling filtration forces in, 160–1
 kidney transplantation, 317
 King's College criteria for liver transplantation, 305
 kinins, 150, 362
 knee-jerk reflex, 247–8
 Krebs's cycle. *See* citric acid cycle
- labetalol, 153
 lactate, 179, 374–5
 lactic acidosis, 375
 Laplace's law, 83
 laryngeal mask airway (LMA), 91–2, 108
 larynx, 24
 lateral medullary syndrome, 215
 l-DOPA, 201
 left ventricular end-diastolic pressure (LVEDP), 131–2
 left ventricular failure (LVF), 132, 139–40
 left ventricular hypertrophy, 424
 left ventricular pressure–volume loop, 136–40

Index

- leptin, 428
 lidocaine, 29, 256
 limbic system, 95, 192
 lipase, 279, 291–2
 lipase inhibitors, 291
 lipogenesis, 380
 lipolysis, 373, 384, 388
 liver
 blood supply, 295
 cell types, 297–8
 centrilobular necrosis, 297–8
 changes of pregnancy, 410
 changes with ageing, 425
 hypocalcaemia, 401
 intraoperative blood flow, 296
 jaundice, 301–2
 macroscopic anatomy, 296
 microscopic anatomy, 296–8
 paediatric, 420
 physiological reserve, 299
 regeneration, 299
 regulation of hepatic blood flow, 295
 respiratory cycle influence on venous blood flow, 295–6
 liver function
 blood reservoir, 304
 changes in cirrhosis, 304, 401
 classification of functions, 299
 drug metabolism, 303
 endocrine, 302
 exocrine, 300–2
 haematological, 304
 immunological, 302
 metabolic, 299–300
 storage, 304
 substances synthesized, 302–3
 liver function tests (LFTs), 304–5
 liver transplantation, 299, 305
 local anaesthetics, 108, 229, 259–61, 369, 413
 loop diuretics, 325
 low flow anaesthesia, 30–1
 low molecular weight heparin (LMWH), 143, 347, 406
 lower airways
 air humidification and, 24
 alveolar–capillary barrier, 27, 40, 42–3, 81
 alveoli cell types, 26–7
 double-lumen ETTs and, 26
 functional anatomy, 24–6
 lung inflation and deflation during breathing, 27–8
 non-respiratory functions of lung, 24, 29
 obstruction, 60–2
 PEEP and, 24
 pneumothorax and, 29
 respiratory functions of lung, 24
 lumbar sympathectomy, 268–9
 lung
 adrenaline effects, 404
 anaesthesia effects, 107–10
 blood flow to, 68–9, 182
 during breath-hold diving, 434–5
 dead space in, 45
 diffusion capacity for carbon monoxide, 42–3
 efficiency of, 40
 elite athletes, 183
 gas exchange in, 24, 26, 38 (*See also* alveolar diffusion)
 gravity effects, 68–70
 inflation and deflation during breathing, 27–8
 lobes, 26
 non-respiratory functions, 24, 29
 O₂ compared with carbon dioxide diffusion in, 40–1
 O₂ loading in, 33
 O₂ toxicity, 102
 perfusion, 68–9 (*See also* ventilation–perfusion mismatch; ventilation–perfusion ratio)
 pneumothorax and, 29
 postoperative function, 109–10
 respiratory functions, 24
 Starling filtration forces in, 160–1
 surface area, 26, 29, 40, 43
 surfactant, 83–4
 transfusion-related injury, 353
 ventilation (*See* alveolar ventilation)
 West zones, 71–3
 lung capacity
 changes of pregnancy, 407
 closing capacity, 47–8, 55
 distinction from lung volumes, 50–1
 functional residual (*See* functional residual capacity)
 general anaesthesia effects, 108
 measurement, 52–5
 types, 50
 lung compliance, 82
 changes with ageing, 422–3
 difference between static and dynamic, 84–5
 factors affecting, 82–3
 FRC and, 51
 hysteresis and, 85–6
 infant respiratory distress syndrome and, 84
 optimum PEEP and, 87
 respiratory compliance distinction from, 82
 static compliance curve and regional differences in lung ventilation, 86–7
 surfactant role in, 83–4
 lung resection, 43, 61
 lung transplantation, 97
 lung volume
 airway resistance, 89, 91
 changes of pregnancy, 407
 changes with ageing, 423
 distinction from lung capacities, 50–1
 general anaesthesia effects, 108
 measurements, 50, 52–6
 in mechanically ventilated patients, 51
 obesity effects, 427
 PVR relationship, 98–9
 types, 50
 luteinizing hormone (LH), 393
 lymph nodes, 365
 lymphatic system, 168–9
 lymphocytes, 363
 lymphoedema, 169
 lymphoid tissue, 363
 lysosomes, 8
 macrophages, 27, 361, 365
 magnesium, 237
 magnesium hydroxide, 285
 magnesium sulphate, 256
 malignant hyperthermia (MH), 242
 mannitol, 208, 325
 Mapleson D. *See* Bain circuit
 Marsh model, 429
 mean arterial pressure (MAP)
 arterial baroreceptor reflex, 170–1
 cardiac output relationship, 121, 123
 CPP relationship to, 202, 207–8
 Cushing's reflex, 172
 factors determining, 153
 importance of minimising fluctuations, 170
 manipulation, 153
 measurement, 152–3
 physiological response to haemorrhage, 172–3
 regulation, 170
 Valsalva manoeuvre effects, 175–6
 mean pulmonary artery pressure (MPAP), 98–9
 mechanical ventilation, 51
 mechanoreceptors, 94–5
 medulla oblongata, 193
 memory cells, 365
 Mendelian inheritance, 11–12
 Mendelson's syndrome, 281, 409
 meninges, 193–4
 mesencephalon, 193
 metabolic acidosis, 331–3
 metabolic alkalosis, 331–7
 metabolic equivalent (MET), 186, 383
 metabolism, 373–80

- adrenaline effects, 403
 amount of ATP generated, 377–8
 ATP production from
 carbohydrates, fats and proteins, 373
 BMR, 383, 420–1
 brain, 203, 208
 carbohydrate, 299, 373, 387
 catecholamine, 404
 cellular respiration, 373
 changes during starvation, 384
 citric acid cycle, 373, 375–6
 cortisol role in, 402
 diabetic ketoacidosis, 382
 drug, 303
 electron transport chain, 36, 373, 376–7
 fat, 179, 299, 373, 378–9, 388
 gluconeogenesis, 299, 380–1
 glycolysis, 179, 299, 373–5
 hypothermia effects, 437
 insulin and glucagon effects, 381–3
 MET, 186, 383
 paediatric, 420–1
 pentose phosphate pathway, 381
 protein, 300, 373, 378–80, 388
 storage of carbohydrates, fats and proteins, 380–1
 stress response, 387–8
 T₃ effects, 396
 metabotropic receptors, 233
 metaraminol, 153, 270
 metathalamus, 193
 methaemoglobin (MetHb), 34–5
 methanol, 332
 methotrexate, 201
 metoclopramide, 281
 microglia, 194
 micturition, 338–40
 midazolam, 428–9
 middle cerebral arteries (MCAs), 194–5
 minimal flow anaesthesia, 30–1
 Minto model, 429
 minute ventilation, 46, 181–2, 407
 mitochondria, 7–8, 81
 mivacurium, 20, 107, 426
 molarity, 319
 monoamine oxidase (MAO) inhibitors, 20
 monocytes, 361
 Monro–Kellie hypothesis, 206–7
 morphine, 314
 motor cortex, 215
 motor end plate, 235–6
 motor nerve fibres, 229
 motor (efferent) neurons, 190–1, 215–16, 235, 247
 motor unit, 244
 multiple sclerosis, 228–9
 multiple-breath nitrogen washout
 method, 54–5
 muscarinic ACh receptors, 270
 muscle. *See* cardiac muscle; skeletal muscle; smooth muscle
 muscle atrophy, 245
 muscle fatigue, 179
 muscle relaxants, 236
 allergic reaction, 369
 denervation hypersensitivity, 237–8
 mechanism of action, 237
 obesity effects, 428–9
 oesophageal effects, 281
 pharmacokinetic differences between children and adults, 421
 physiological changes with ageing, 426
 respiratory system effects, 107, 109–10
 transport across placenta, 413
 muscle spindle, 95, 246–7
 muscle tone, 248
 muscular dystrophy, 244–5
 muscular system, 1
 myasthenia gravis (MG), 105, 237, 412
 myelination, 227–9
 myocardial contractility, 121–3, 137–8, 156–7, 172, 180
 myocardial infarction (MI), 141–3
 myocardial injury, 143
 myocardial ischaemia. *See* cardiac ischaemia
 myocardium, 111–12, 114
 myogenic autoregulation, 149–50, 250
 myoglobin, 36
 myosin, 240–4
 myotonia congenita, 245
 myotonic dystrophy, 245
 Na⁺/K⁺-ATPase, 16, 223
 natural killer (NK) cells, 361
 negative feedback, 3–4, 393–4
 neostigmine, 20
 nephron, 307–8, 313–14
 Nernst equation, 222
 nerve action potential, 225
 differences from cardiac action potential, 252–3
 effects of demyelination, 228–9
 effects of local anaesthetics, 229
 effects of myelination, 227–9
 events leading to, 225–6
 propagation along nerve axons, 226–7
 refractory period, 229–30
 nerve fibres, 191, 229
 nervous system, 1
 CNS (*See* central nervous system)
 divisions, 190–1
 eye, 276–7
 functions, 189
 neuron structure, 189–90
 neuron types, 190
 peripheral nerve structure, 191
 PNS (*See* peripheral nervous system)
 neural signalling, 189
 neuraxial blockade, 153, 340, 408–9
 neurogenic bladder, 339
 neurogenic shock, 217
 neuroglia, 194
 neuromuscular blocking agents, 107, 109–10, 426
 neuromuscular junction (NMJ), 235–8
 neurons
 structure, 189–90
 types, 190
 neuropathic pain, 275
 neurotransmitters, 201, 231–2
 Ca²⁺ effects, 399
 diffusion, degradation and reuptake, 235
 NMJ, 235–7
 release, 232–3
 smooth muscle input from, 250
 neurotrophils, 360
 nicotinic ACh receptors, 270
 nifedipine, 433
 nitrates, 115
 nitric oxide (NO), 35, 99, 150, 162, 341
 nitrogen narcosis, 435
 nitrous oxide (N₂O), 41, 107, 204, 234
 nociception, 272
 nociceptive pain, 272
 nociceptor fibres, 272–3
 nociceptors, 272
 non-depolarising muscle relaxants, 237, 281, 421, 426, 428–9
 non-steroidal anti-inflammatory drugs (NSAIDs), 108, 310–11, 371–2
 noradrenaline, 29, 122, 153, 201, 235, 261, 268, 270–1, 274, 402–4
 nucleobases, 9–10
 nucleus, cell, 6–7
 nutrients. *See also* dietary nutrients
 placental exchange, 411
 regulation, 2
 obesity, 22, 43, 427–9
 obstructive lung disease, 56–61, 90–1
 obstructive sleep apnoea (OSA), 22–3, 427
 occipital lobe, 192
 oesophageal Doppler (CardioQ), 128–9
 oesophagus, 280–1
 oestrogen, 406
 oligodendrocytes, 194
 omeprazole, 285
 ondansetron, 288

Index

- one-lung ventilation, 100
 opioids
 effects on CBF, 204
 endogenous, 273–4
 immune system depression, 369–70
 oesophageal effects, 281
 overdose, 78
 PONV, 288
 post-operative urinary retention, 340
 reduced stress response, 389
 respiratory system effects, 107
 spinal cord injury patients, 220
 transport across placenta, 413
 ventilation control effects, 96
 optic disc, 277
 optic neuropathy, 278
 oral anticoagulant therapy, 347–8
 oral contraceptive pill, 303
 oral rehydration therapy (ORT), 290
 organelles, 7–8
 organs
 development, 1
 systems, 1–2
 Orlistat, 291
 osmolality, 319
 osmolar gap, 319
 osmolarity, 319–23, 325
 osmotic diuretics, 208, 325
 oxidative phosphorylation, 179, 376–7
 oxygen (O_2)
 alveolar diffusion of, 40–3
 binding, 31–2, 35–6
 buffer, 51
 dissociation, 32–3, 36
 effects on CBF, 203–4
 Fick principle applied to, 125
 harmful levels of, 102–3
 regulation, 2
 storage and consumption, 30–1
 oxygen administration
 at different shunt fractions, 67
 shunt response, 65
 for \dot{V}/\dot{Q} mismatch, 65, 69–70
 oxygen cascade, 80–1
 oxygen consumption, 30–1
 changes of pregnancy, 407
 global (See global O_2 consumption)
 paediatric, 419
 oxygen content equation, 30
 oxygen delivery
 foetal, 413–14
 global, 74–6
 HFNO therapy, 23
 minimal flow anaesthesia, 30–1
 oxygen demand, 114–15
 oxygen extraction ratio (OER), 75, 141
 oxygen flux equation, 74
 oxygen partial pressure (PO_2)
 alveolar (See alveolar partial pressure of oxygen)
 arterial (See arterial tension of oxygen)
 along O_2 cascade, 80–1
 oxygen toxicity, 102–3, 435
 oxygen transport
 blood transfusion and, 33
 carbon monoxide poisoning and, 35–6
 cyanide poisoning and, 36
 haemoglobin, 30–2, 34
 methaemoglobin and, 34–5
 minimal flow anaesthesia and, 30–1
 myoglobin, 36
 O_2 storage and consumption, 30–1
 oxyhaemoglobin dissociation curve, 32–3, 432
 plasma, 30
 red blood cells, 31
 sickle cell disease and, 34–5
 oxygenation
 distinction from ventilation, 104
 foetal, 413–15
 intensive care and, 103
 oxygen-carrying solutions, 355
 oxyhaemoglobin dissociation curve, 32–3, 432
 oxymyoglobin dissociation curve, 36
 oxytocin, 4, 394–5
 pacemaker cells, 250, 252, 255–7
 pacemakers, 113–14
 packed RBCs, 352
 paediatric physiology, 418
 choice of ETT for children, 418–19
 differences between children and adults, 418–21
 pharmacokinetic differences between children and adults, 421
 pain, 272
 allodynia, 275
 classification, 272
 distinction from nociception, 272
 hyperalgesia, 275
 modulation mechanisms, 273–4
 neuropathic, 275
 nociceptive, 272
 nociceptors, 272
 postoperative, 110
 role of sympathetic nervous system, 275
 signal pathways to brain, 273
 types of nociceptor fibres, 272–3
 pancreas, 291–3
 pancreatitis, 292
 paracetamol, 298, 305
 parasympathetic nervous system, 1, 151, 250, 259–60, 267–70, 277, 280, 294
 parathyroid hormone (PTH), 399–401, 406
 parietal cells, 284–5
 parietal lobe, 192
 passive immunisation, 365–6
 passive transport, 14–16
 Pasteur point, 81
 patellar reflex, 247–8
 patency, upper airway, 21
 peak expiratory flow rate (PEFR), 56–8
 penetrating eye injury, 278
 penicillins, 311, 314
 pentose phosphate pathway (PPP), 381
 perfluorocarbons, 355
 perfusion. *See also*
 ventilation–perfusion mismatch;
 ventilation–perfusion ratio
 gravity effects on, 68–9
 problems with, 69
 West zone variations, 71–3
 peripheral arteries, 156
 peripheral nerves, 191
 peripheral nervous system (PNS), 1, 190–1, 217
 peripheral oedema, 160–1
 pethidine, 413
 pH, 329
 Henderson-Hasselbalch equation, 330
 regulation of, 2, 332–4
 temperature dependence, 336
 phagocytes, 361
 phagocytosis, 17, 302
 pharmacokinetics
 differences between children and adults, 421
 obesity effects, 428–9
 physiological changes with ageing, 426
 pharynx, 21–2
 phenotype, 11–12
 phenylephrine, 153, 270, 426
 phenytoin, 201, 421
 phosphodiesterase inhibitors, 344
 phospholipid bilayer, 13
 physiological dead space, 45, 48–9
 physiology, 1
 pia mater, 194
 pineal gland, 201
 pinocytosis, 17, 159, 200
 pituitary adenoma, 395
 pituitary gland, 201, 387, 392–5
 pK_a , 329–30
 placenta
 anatomy and functions, 411–12
 drug transport, 413

- foetal O₂ delivery, 413–14
 mechanisms of crossing, 412–13
 pre-eclampsia, 411–12
 transfer of antibodies, 412
- plasma, 371
 Ca²⁺ in, 399–401
 CO₂ dissolved in, 37
 CSF compared with, 199
 functions of albumin, 371–2
 O₂ dissolved in, 30
 proteins, 371
- plasma cells, 365
- plasma osmolality, 319–20, 325
- plasma volume, 318
 altitude adaptations, 432
 changes of pregnancy, 408
 physiological response to high, 325–6
 physiological response to low, 324–5
 regulation of, 318–19, 325
- plasminogen, 348–9
- platelet concentrate, 352–3
- platelets, 341–4, 409
- pneumocytes, 26
- pneumonectomy, 43
- pneumonia, 100
- pneumotaxic centre, 93
- pneumothorax, 29
- polycythaemia, 358
- polycythaemia rubra vera (PRV), 358–9
- pons, 193
- portal vein, 163, 295
- positive end-expiratory pressure (PEEP)
 airway resistance, 91
 alveolar dead space and, 45–6
 extrinsic, 24
 FRC and, 51
 general anaesthesia effects, 108
 hepatic blood flow effects, 295
 optimum level of extrinsic, 87
 for patients with diffusion impairment, 43
 physiological, 24
 PVR effects in one-lung ventilation, 100
 venous return effects, 164
- positive feedback, 4–5
- positive pressure ventilation, 164, 295
- postoperative nausea and vomiting (PONV), 288
- postoperative respiratory function, 109–10
- post-operative urinary retention (POUR), 339–40
- post-operative visual loss (POVL), 278
- potassium (K⁺)
 blood transfusion, 354
 denervation hypersensitivity, 237–8
 kidney regulation of, 326–8
 muscle fatigue, 179
 resting membrane potential, 221–3, 252
- potassium channel blockers, 255–6
- potassium channel openers, 115
- potassium channels, 225–6, 233, 253–5
- potassium-sparing diuretics, 325
- prasugrel, 344
- preconditioning, ischaemia, 144
- pre-eclampsia, 411–12
- pregnancy
 alterations in endocrine function, 405–6
 challenges of general anaesthesia, 407
 glycosuria in, 314, 409
 IVC compression, 164–5
 physiological changes and anaesthesia, 406–10
 pre-eclampsia, 411–12
 Rhesus disease, 351
- preload, 121–2, 136–7, 180
- preoperative carbohydrate loading, 385
- preoperative fasting, 286–7
- pre-oxygenation, 52, 55
- pressure–volume area (PVA), 139
- pressure–volume graphs, 90–1
- pressure–volume loop
 left ventricular, 136–40
 right ventricular, 139–40
- prilocaine, 35
- primary brain injury, 209
- probenecid, 314
- procainamide, 256
- progesterone, 405–6, 410
- prolactin (PRL), 393–4, 406
- propofol, 107, 201, 204, 234, 281, 413, 428–9
- propranolol, 256
- proprioception, 246
- propylthiouracil, 398
- prostacyclin (PGI₂), 162, 341
- prostaglandins, 310–11
- protein
 digestion and absorption, 290–1
 metabolism, 300, 373, 378–80, 388
 storage, 380–1
 synthesis, 300, 302
- proteinuria, 409–10
- prothrombin time (PT), 305, 346–7, 371–2
- proton-pump inhibitors (PPIs), 285
- proximal convoluted tubule (PCT), 307, 313–14
- pulmonary artery catheter (PAC), 72–3, 101, 125–7
- pulmonary artery pressure, 45, 71–2
- pulmonary blood flow, 68–9, 182
- pulmonary capillary wedge pressure (PCWP), 72–3, 101, 121
- pulmonary circulation
 distinction from systemic circulation, 145–6
 factors affecting PVR, 98–9
 HPV in clinical practice, 99–100
 lung transplantation and, 97
 PEEP, PVR and one-lung ventilation, 100
 pressure waveform changes when floating balloon-tipped PACs, 101
 PVR compared with SVR, 97–8
 reason for normal low pressure, 97
 unique features, 97
- pulmonary embolism (PE), 70
- pulmonary function tests (PFTs), 43, 56–62
- pulmonary haemorrhage, 43
- pulmonary oedema, 43, 100, 160–1
- pulmonary surfactant, 83–4
- pulmonary vascular resistance (PVR), 97–8, 100, 121
- pulse contour analysis, 127–8, 156
- Purkinje fibres. *See* conducting cells
- pyramidal tract. *See* corticospinal tract
- quinidine, 256
- radioactive xenon-133, 205
- radioiodine, 398
- ranitidine, 285
- ranolazine, 115
- rapid sequence induction (RSI), 55, 220
- reactive oxygen species (ROS), 102, 425
- re-breathing, 47
- red blood cells (RBCs)
 antigens, 350–1
 carbonic anhydrase reactions in, 37–8
 causes of anaemia, 356–7
 packed, 352
 polycythaemia, 358–9
 in sickle cell disease, 34
 steps in production, 356
 structure, 31
- refeeding syndrome, 385
- referred cardiac pain, 141–2
- reflexes, 247–8. *See also* cardiovascular reflexes
- refractory period, 229–30, 255
- remifentanyl, 20, 428–9
- renal blood flow (RBF), 309–11
- renal clearance, 314–16
- renal excretion, 314

Index

- renal filtration, 309–10, 313, 315–16
 renal medulla, 320–3
 renal replacement therapy, 316–17
 renin-angiotensin-aldosterone axis, 310, 408
 reperfusion injury, 143–4
 reproductive system, 2
 residual volume (RV), 50, 52
 respiratory acidosis, 330–1
 respiratory alkalosis, 331
 respiratory centre, 93–5, 104–5, 107–8, 171
 respiratory compliance, 82–3, 407
 respiratory cycle, 295–6
 respiratory failure, 104
 development in myasthenia gravis, 105
 type 1, 104
 type 2, 104
 respiratory quotient (R), 77–8
 respiratory sinus arrhythmia, 171, 419
 respiratory system, 1
 altitude adaptations, 431–2
 anaesthetic drug effects, 107–8
 changes at birth, 416–17
 changes of pregnancy, 406–7
 changes with ageing, 422–4
 difference between oxygenation and ventilation, 104
 effects of acid-base disturbances, 335
 elite athletes, 183
 exercise effects, 181–2
 general anaesthesia effects, 108–10
 lower airways, 24–9
 obesity effects, 427
 paediatric, 418–19
 regulation of pH, 332–3
 spinal cord injury effects, 216–17
 upper airways, 21–3
 resting membrane potential (RMP)
 Ca²⁺ role in, 399
 cardiac muscle cells, 252
 contribution of Na⁺/K⁺-ATPase, 223
 effects of electrolyte disturbances, 223
 electrolyte disturbances, 223
 Goldman-Hodgkin-Katz equation, 222–3
 Nernst equation, 222
 production, 221–2
 restrictive lung disease, 56–61, 90–1
 retina, 102, 276
 reverse Fick principle, 74
 Reynolds number, 89
 Rhesus blood group system, 350–1, 412
 Rhesus disease, 351
 rhinitis, allergic, 368–9
 rhombencephalon, 193
 ribonucleic acid (RNA), 9–10
 right ventricular failure (RVF), 132
 right ventricular pressure–volume loop, 139–40
 rivaroxaban, 347–8
 rocuronium, 278
 salbutamol, 270–1, 327
 salicylate, 332
 saliva, 279–80
 sarcomere, 131–2, 240, 244, 249
 Schnider model, 429
 SCUBA diving, 435
 secondary brain injury, 209
 secretin, 293
 sedatives, 22–3, 76
 segmental inhibition of pain, 273–4
 selective serotonin reuptake inhibitors (SSRIs), 235, 274
 sensory afferent pathways, 213–15
 sensory nerve fibres, 229
 sensory (afferent) neurons, 190–1, 213, 247
 septic shock, 153
 septicaemia, blood transfusion, 353
 serotonin, 151, 235, 274, 391
 sevoflurane, 107, 204
 shunt equation, 65–7
 shunts, 64–5, 67, 199
 sickle cell disease, 11, 34–5
 silent myocardial infarction, 142
 simple diffusion, 14–15, 158, 200–1
 Singh-Vaughan Williams classification, 255–6
 skeletal muscle
 anatomy, 239
 arteriolar vasoconstriction and vasodilatation, 151
 atrophy, 245
 changes with ageing, 425
 differences from smooth muscle, 249
 disorders, 244–5
 dynamic compared with static activation, 178
 elite athletes, 184
 energy sources for contraction, 179
 excitation-contraction coupling, 241–2
 exercise effects, 180
 fatigue, 179
 fibre types, 178–9
 force of contraction, 244
 functions, 239
 malignant hyperthermia, 242
 mechanism of contraction, 242–4
 motor units, 244
 physiological changes in anticipation of exercise, 180
 sarcomeres, 240, 244
 stress response effects, 388
 thick and thin filaments, 240–1
 tone, 248
 skeletal system, 2
 skin, 2, 425
 sleep, 21–2, 392
 sleep apnoea, 22–3, 427
 small intestine, 289–90, 293–4
 smooth muscle
 adaptation to function, 251
 differences from skeletal muscle, 249
 excitation-contraction coupling, 250–1
 excitatory inputs, 250
 intestinal, 293–4
 locations in body, 249
 mechanism of contraction, 251
 types, 249
 sodium (Na⁺), 2, 221–4, 252, 318–19, 323–4
 sodium channel blockers, 255–6
 sodium channels, 225–6, 229, 253–5
 sodium citrate, 285
 sodium nitroprusside, 153
 sotalol, 255–6
 spinal anaesthesia, 340, 389
 spinal cord, 191
 anatomy, 211
 anterior spinal artery syndrome, 212–13, 218
 blood supply, 212–13
 corticospinal tract, 212, 215–16
 cross-section, 211–12
 meninges, 193–4
 paediatric, 420
 sensory afferent pathways, 213–15
 sensory loss, 214–15
 spinal cord injury
 classification, 216
 effects related to level of complete injury, 216–18
 initial management, 219–20
 neurogenic bladder, 339
 patterns of incomplete, 218–19
 spinal shock, 248, 339
 spinocerebellar tract, 212
 spinothalamic tract, 211, 213–15
 spirometry
 clinical uses and equipment, 56
 dynamic, 56
 expiratory flow–volume curve, 58–60
 FEV₁, FVC and PEFr
 measurements, 56–8
 flow–volume loop, 60–2
 Guillain-Barré syndrome and, 57–8
 lung resection preoperative work-up, 61

- lung volume measurements, 50, 52, 56
 stridor and, 62
 variables measured, 56
 spironolactone, 325
 stagnant hypoxia, 63
 staircase effect, 123
 Starling filtration equation, 159, 315
 Starling filtration forces
 in capillaries, 159–61
 in kidney, 315
 Starling's law of the heart, 131–2, 134
 starvation, 384–6
 static compliance, 84–7
 static exercise, 178
 static lung volumes. *See* lung volume
 statins, 115–16
 stellate ganglion blockade, 268, 277
 steroid hormones, 391
 Stewart approach to acid-base
 physiology, 336–7
 Stewart-Fencel-Story approach, 336–7
 Stewart–Hamilton equation, 125–6
 stomach, 283–8
 streptokinase, 348
 stress response, 387–9
 stridor, 62
 stroke, 195–6
 stroke volume (SV), 119, 131–2, 153, 183
 stroke volume index (SVI), 123
 subarachnoid space, 194
 subcutaneous drug administration, 169
 subdural space, 194
 subthalamus, 193
 sulphonamide antibiotics, 35
 surfactant, lung, 83–4
 suxamethonium, 20, 107, 220, 237–8, 242, 278, 281, 369, 410, 421, 426, 428–9
 swallowing, 280–1
 Swan–Ganz catheter, 101, 125–7
 sympathetic blockade, 268–9, 277
 sympathetic nervous system, 1, 151, 250, 259–60, 267–70, 275, 277, 280, 294–5, 310, 382, 387, 391–2
 synapse, 231–5. *See also* neuromuscular junction
 synaptic cleft, 232–3
 syndrome of inappropriate ADH secretion, 323
 syringomyelia, 214–15
 systemic circulation. *See also* arterial system; venous system
 blood velocity and flow, 145–7
 capillaries, 146–7, 158–61
 components, 145
 cross-sectional area, 145–7
 distinction from pulmonary circulation, 145–6
 endothelium, 162
 foetal, 99, 415–17
 functions, 145
 lymphatic system, 168–9
 systemic inflammatory response syndrome (SIRS), 362
 systemic lupus erythematosus, 369, 412
 systemic vascular resistance (SVR), 97–8, 121, 151–3, 156–7
 systole, 117
 systolic blood pressure (SBP), 152–3
 tachycardia, 119–20, 122–3, 172
 tamsulosin, 270
 target controlled infusion (TCI), 429
 telencephalon, 192
 temperature regulation, 3
 adverse effects of hypothermia, 437–8
 adverse effects of intraoperative hypothermia, 438
 altitude adaptations, 432–3
 changes with ageing, 425
 effects of anaesthesia on normal mechanisms, 436–7
 exercise effects, 182
 hypothalamus role in, 392
 mechanisms, 436
 paediatric, 421
 venous system role in, 163
 temporal lobe, 192
 tetanus Ig, 366
 thalamus, 95, 192
 thiazide diuretics, 325
 thick filaments, 240–1
 thin filaments, 240–1
 thiopentone, 201, 204, 234, 281, 371–2, 413, 421, 428–9
 thoracic cage compliance, 82–3
 thrombin, 162, 341–6
 thrombin time (TT), 347
 thromboelastography, 348
 thrombolysis, 348
 thrombosis, 341, 358–9, 388. *See also* clotting
 thymus, 363
 thyroid gland, 396–9, 406
 thyroid-stimulating hormone (TSH), 393, 397–8, 406
 thyrotropin-releasing hormone (TRH), 397, 406
 thyroxine (T_4), 396–8, 406
 ticagrelor, 344
 tidal breathing, 27–8
 tidal volume (V_T), 50–1
 tirofiban, 344
 tissue factor (TF), 342, 344–5
 tissue plasminogen activator (t-PA), 341, 348–9
 tonsillectomy, 24
 total intravenous anaesthesia (TIVA), 429
 total lung capacity (TLC), 50, 52
 trachea, 80, 418–19
 tracheobronchial tree, 25–6
 tracheomalacia, 398–9
 trait, 11
 tranexamic acid, 348–9
 transcranial Doppler ultrasonography, 204
 transfer factor of the lung for carbon monoxide (TLCO), 42–3, 61
 transfusion. *See* blood transfusion
 transfusion associated circulatory overload (TACO), 353
 transfusion-related acute lung injury (TRALI), 353
 transfusion-related
 immunomodulation (TRIM), 370
 transitional circulation, 417
 trans-oesophageal echocardiography (TOE), 129
 transverse (T)-tubules, 239, 242, 249–50
 traumatic brain injury (TBI), 209–10
 Treppe effect, 123
 tricarboxylic acid cycle. *See* citric acid cycle
 tricyclic antidepressants (TCAs), 274
 triglycerides, 291, 380
 triiodothyronine (T_3), 396–8, 406
 troponin, 141, 143, 241–2, 249
 tuberculosis, 369
 turbulent gas flow, 88–90
 unfractionated heparin therapy, 347
 universal donors, 352
 universal recipients, 352
 upper airways, 21–3, 60, 62, 89
 urea, 300, 316, 323
 uric acid, 409
 urinary continence, 338
 urinary retention, 339–40
 urinary system, 2
 urine, 338
 uterine autotransfusion, 171
 uterine contractions, 4
 uterus, 249
 vaccination, 365–6
 Valsalva manoeuvre, 175–7
 valvular heart disease, 120
 varicella zoster Ig, 366
 vasoconstriction, 150–1, 172, 341–2, 434
 vasoconstrictors, 162

Index

- vasodilatation, 150–1, 361
 vasodilators, 162
 vasopressin, 153
 vasopressors, 153, 426
 veins, 163–4
 vena cava, 164–5
 venous pressure, 71–2, 164–5, 176. *See also* central venous pressure
 venous pressure waveforms, 166–7
 venous return, 163–5, 173
 venous system, 147, 163–5, 424, 428
 ventilation
 alveolar (*See* alveolar ventilation)
 dead-space, 46
 distinction from oxygenation, 104
 mechanical, 51
 minute, 46, 181–2, 407
 West zone variations, 71–3
 ventilation control, 93–6, 198
 ventilation–perfusion (\dot{V}/\dot{Q}) mismatch, 65, 69–70, 109
 ventilation–perfusion (\dot{V}/\dot{Q}) ratio, 68–70
 ventilatory failure, 104–5
 ventral respiratory group (VRG), 93
 ventricle, heart, 111, 117–19
 ventricular contraction, 117–18, 131–2
 ventricular septal defect (VSD), 64
 verapamil, 256
 vertebral arteries, 194–5
 visual loss, post-operative, 278
 vital capacity (VC), 50
 vitamin B₁₂, 283–4
 vitamin D, 400–1
 vitamin K, 347, 420
 vitreous humour, 276
 $\dot{V}O_{2\text{ max}}$, 74, 182–3
 volatile anaesthetic agents, 153
 airway resistance, 91
 alveolar diffusion of, 41
 effects on CBF, 204
 at high altitude, 433
 HPV effects, 100
 immune system depression, 370
 malignant hyperthermia, 242
 obesity effects, 428–9
 oesophageal effects, 281
 pharmacokinetic differences between children and adults, 421
 physiological changes with ageing, 426
 PONV, 288
 pregnancy considerations, 410
 respiratory system effects, 107
 transport across BBB, 201
 volutrauma, 51
 vomiting, 287–8
 von Willebrand disease, 345
 von Willebrand factor (vWF), 162, 342, 345
 warfarin, 347, 371–2
 waste product removal, 2
 water. *See also* diving
 distribution in body, 318
 physiological changes during head-out immersion, 434
 water balance, 2
 ADH actions at kidney, 320–1
 body fluid compartments, 318, 421
 disorders of osmolarity, 323
 diuretic effects, 324–5
 high osmolarity of renal medulla, 320–3
 hypothalamus role in, 392
 osmolality, 319
 osmolarity, 319
 physiological response to high plasma volume, 325–6
 physiological response to low plasma volume, 324–5
 plasma osmolarity, 319–20, 325
 regulation of plasma volume, 318–19, 325
 West zones, 71–3
 Windkessel effect, 155
 work of breathing, 88–92, 108
 xenon-133, 205
 X-linked recessive inheritance, 12